A multi-compound dietary supplement to improve the well-being of symptomatic uncomplicated diverticular disease

View at publisher Summarise with VIRAT
Authors: Lorenzo Bertani, Lucia Chico, Linda Balestrini, Giulia Della Scala, Alissa Satriano, Raffaele Manta
Cited by: 0
References: 40

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Current treatment strategies for symptomatic uncomplicated diverticular disease (SUDD) remain controversial. Nutraceuticals could be potential adjuvant treatments to reduce symptoms and improve Quality of Life (QoL). METHODS: A retrospective analysis of data collected in a real-world clinical setting was performed on SUDD patients with persistent diarrheal symptoms following rifaximin therapy. A synbiotic anti-inflammatory dietary supplement (SADS), containing Lactobacillus rhamnosus GG, Hericium erinaceus, berberine, quercetin, palmitoylethanolamide, and Undaria, was administered daily for one month to evaluate its effectiveness in reducing these symptoms. Outcome measures included daily bowel movement frequency, Abdominal Pain Score, treatment satisfaction, and fecal calprotectin levels, and were evaluated at baseline (T0) and after one month (T1). RESULTS: Data from 54 SUDD patients (mean age: 53.2±11.3 years) were collected. Daily bowel movements significantly decreased after SADS treatment (T1) compared to T0 (2.18±0.8 vs. 3.8±0.7; P

Fields of Study & Subjects

Diverticular Disease and Complications Gastrointestinal motility and disorders Inflammatory Bowel Disease

Publication details

Journal / source
Minerva Gastroenterology
Volume
72
Issue
2
Pages
169–177
Publication date
30 March 2026
Language
EN